OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 10 00:45

OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains

Zacks Jan 8 21:35

H.C. Wainwright Maintains Opko Health(OPK.US) With Buy Rating, Maintains Target Price $3

Futu NewsJan 8 20:34 · Ratings

Opko Health's Promising Pipeline: Buy Rating Backed by Innovative Trials and Strategic Collaborations

TipRanksJan 8 20:25 · Ratings

Merck & Compnay and OPKO Health Shares Are Trading Higher After the Companies Announced a License and Collaboration Agreement to Develop an Epstein-Barr Virus Vaccine.

BenzingaJan 8 00:15

OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck

MT NewswiresJan 8 00:09